Overview

Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

Status:
Terminated

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the overall survival (OS) for Orantinib in combination with transcatheter arterial chemoembolization (TACE) versus placebo in combination with TACE in patients with unresectable hepatocellular carcinoma (HCC).

Phase:

Phase 3

Details

Lead Sponsor:

Taiho Pharmaceutical Co., Ltd.

Treatments:

Orantinib